The circadian hippocampus and its reprogramming in epilepsy: impact for chronotherapeutics

Konrad J. Dębski, Nicholas Ceglia, Antoine Ghestem, Anton Ivanov, Giulio Emilio Brancati, Sonja Bröer, Anna Bot, Johannes Alexander Müller, Susanne Schoch, Albert J. Becker, Wolfgang Löscher, Maxime Guye, P. Sassone‐Corsi, Katarzyna Łukasiuk, Pierre Baldi, Christophe BernardbioRxiv 2017 · DOI

TL;DR

This study reveals that the hippocampus exhibits a daily "remapping" of its gene and protein expression, creating distinct functional states throughout the day and night. This circadian rhythm is significantly disrupted in epilepsy, impacting drug targets and suggesting a need for chronotherapeutics tailored to the time of day.

What Problem Does This Paper Address?

The paper addresses the fundamental question of whether the brain, specifically the hippocampus, exhibits daily (circadian) rhythms in gene and protein expression, and how these rhythms are altered in disease states like epilepsy. While circadian rhythms are known to influence many bodily organs, their role in the complex molecular architecture of the brain, particularly in neurological disorders, is less understood. This knowledge gap is critical because disruptions in these rhythms can contribute to disease pathology and affect the efficacy of treatments. The authors aim to provide a comprehensive resource of circadianly regulated genes and proteins in the hippocampus, both in healthy and epileptic conditions, to inform future research and therapeutic strategies.

Methods

The researchers employed a multi-omics approach, combining transcriptomics (using Affymetrix microarrays) and proteomics to identify oscillating genes and proteins in the mouse hippocampus. They utilized cluster analysis and statistical methods (JTK_CYCLE, Cyber-T, ANOVA) to identify rhythmic transcripts and proteins and to compare expression patterns between control and epilepsy models. Functional analysis was performed using DAVID bioinformatics to understand the biological pathways affected. Additionally, they assessed metabolic activity using NAD(P)H imaging in hippocampal slices and measured seizure susceptibility using the pentylenetetrazole (PTZ) test.

Datasets

The study utilized transcriptomic data from microarray experiments and proteomic data from mass spectrometry analysis of mouse hippocampi. These datasets were generated from control mice and mice with experimentally induced temporal lobe epilepsy (TLE).

Key Insights and Ideas

  • Hippocampal "Remapping": The hippocampus doesn't maintain a static molecular state; it undergoes a daily "remapping" of its gene and protein landscape, suggesting distinct functional modes for different times of the day.
  • Epilepsy Disrupts Circadian Rhythms: Temporal lobe epilepsy significantly alters this daily remapping, with a substantial increase in the number of oscillating transcripts and a low overlap with control patterns. This implies a fundamental reprogramming of the hippocampus's circadian clock in epilepsy.
  • Time-Dependent Drug Efficacy: The altered circadian regulation in epilepsy means that the targets of antiepileptic drugs may also exhibit different temporal expression patterns, making drug efficacy time-dependent. This highlights the potential for chronotherapeutics.
  • Metabolic Dysregulation in Epilepsy: Glycolysis in hippocampal slices shows a time-dependent alteration in TLE, being decreased at one time point and increased at another, further underscoring the circadian disruption and its impact on fundamental cellular processes.
  • Seizure Susceptibility is Circadian: Seizure incidence itself follows a circadian pattern, suggesting that the timing of seizures is not random but influenced by the animal's internal clock.

Key Results

  • Approximately 10% of hippocampal genes (1256 transcripts) were found to oscillate daily in control mice.
  • In experimental TLE, this number increased by 30% to 1650 oscillating transcripts, with only 29% overlapping with control patterns.
  • Proteomic analysis identified 170 oscillating peptides in controls and 337 in TLE.
  • Key circadian clock genes showed altered oscillation amplitudes and phase shifts in TLE.
  • Metabolic activity, specifically glycolysis, showed significant time-dependent differences in TLE compared to controls.
  • Seizure susceptibility exhibited a clear circadian pattern, with the highest probability around ZT15.

Limitations and Future Work

  • Cell-Type Specificity: The study analyzed whole hippocampal tissue, which lumps together different cell types. Future work should focus on cell-type specific analysis to understand how circadian rhythms and their reprogramming differ across neurons, astrocytes, and oligodendrocytes.
  • Epigenetic Mechanisms: While the study identified potential epigenetic mechanisms (e.g., Runx1, Hdac1/2) involved in the reprogramming of circadian regulation in TLE, further investigation is needed to elucidate these mechanisms.
  • Causality of Reprogramming: It remains to be determined whether the reprogramming of circadian behavior in epilepsy is a cause or a consequence of seizures, altered sleep-wake cycles, or a homeostatic mechanism.
  • Chronotherapeutic Development: The findings strongly suggest the need for chronotherapeutic approaches, but further research is required to translate these findings into effective drug delivery strategies.
  • Broader Neurological Disorders: The authors propose that similar reprogramming of circadian rhythms may occur in most neurological disorders, warranting further investigation across a wider range of conditions.

Summary updated

Abstract

Abstract Gene and protein expression displays circadian oscillations in numerous body organs. These oscillations can be disrupted in diseases, thus contributing to the disease pathology. Whether the molecular architecture of cortical brain regions oscillates daily and whether these oscillations are modified in brain disorders is less understood. We identified 1200 daily oscillating transcripts in the hippocampus of control mice. More transcripts (1600) were oscillating in experimental epilepsy, with only one fourth oscillating in both conditions. Proteomics confirmed these results. Metabolic activity and targets of antiepileptic drugs displayed different circadian regulation in control and epilepsy. Hence, the hippocampus, and perhaps other cortical regions, shows a daily remapping of its molecular landscape, which would enable different functioning modes during the night/day cycle. The impact of this remapping in brain pathologies needs to be taken into account not only to study their mechanisms, but also to design drug treatments and time their delivery.
BibTeX
@misc{debski2017circadian,
  author = {Konrad J. Dębski and Nicholas Ceglia and Antoine Ghestem and Anton Ivanov and Giulio Emilio Brancati and Sonja Bröer and Anna Bot and Johannes Alexander Müller and Susanne Schoch and Albert J. Becker and Wolfgang Löscher and Maxime Guye and P. Sassone‐Corsi and Katarzyna Łukasiuk and Pierre Baldi and Christophe Bernard},
  title = {{The circadian hippocampus and its reprogramming in epilepsy: impact for chronotherapeutics}},
  year = {2017},
  doi = {10.1101/199372},
  howpublished = {bioRxiv},
}
Figure